NO20054170L - Antistoff mot human IL-21 reseptor og anvendelser derav - Google Patents
Antistoff mot human IL-21 reseptor og anvendelser deravInfo
- Publication number
- NO20054170L NO20054170L NO20054170A NO20054170A NO20054170L NO 20054170 L NO20054170 L NO 20054170L NO 20054170 A NO20054170 A NO 20054170A NO 20054170 A NO20054170 A NO 20054170A NO 20054170 L NO20054170 L NO 20054170L
- Authority
- NO
- Norway
- Prior art keywords
- receptor
- human
- antibody
- antibodies
- diseases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45433603P | 2003-03-14 | 2003-03-14 | |
PCT/US2004/007444 WO2004083249A2 (en) | 2003-03-14 | 2004-03-12 | Antibodies against human il-21 receptor and uses therefor |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20054170D0 NO20054170D0 (no) | 2005-09-07 |
NO20054170L true NO20054170L (no) | 2005-12-05 |
Family
ID=33029874
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20054170A NO20054170L (no) | 2003-03-14 | 2005-09-07 | Antistoff mot human IL-21 reseptor og anvendelser derav |
Country Status (20)
Country | Link |
---|---|
US (2) | US7495085B2 (ko) |
EP (2) | EP1603949B9 (ko) |
JP (1) | JP4914209B2 (ko) |
KR (1) | KR20050119120A (ko) |
CN (2) | CN1777621A (ko) |
AR (1) | AR043616A1 (ko) |
AT (1) | ATE456581T1 (ko) |
AU (1) | AU2004221876B2 (ko) |
BR (1) | BRPI0408315A (ko) |
CA (1) | CA2518371A1 (ko) |
CL (1) | CL2004000534A1 (ko) |
CO (1) | CO5660297A2 (ko) |
DE (1) | DE602004025332D1 (ko) |
ES (1) | ES2340280T3 (ko) |
MX (1) | MXPA05009556A (ko) |
NO (1) | NO20054170L (ko) |
NZ (1) | NZ542306A (ko) |
RU (1) | RU2005131852A (ko) |
WO (1) | WO2004083249A2 (ko) |
ZA (1) | ZA200507067B (ko) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6057128A (en) | 1998-03-17 | 2000-05-02 | Genetics Institute, Inc. | MU-1, member of the cytokine receptor family |
WO2004007682A2 (en) * | 2002-07-15 | 2004-01-22 | Wyeth | Methods and compositions for modulating t helper (th) cell development and function |
RU2005131852A (ru) | 2003-03-14 | 2006-04-20 | Уайт (Us) | Антитела против человеческого рецептора il-21 и их применение |
CN1849131A (zh) * | 2003-03-21 | 2006-10-18 | Wyeth公司 | 用白介素-21/白介素-21受体的激动剂治疗免疫性疾病 |
EP1983000B1 (en) | 2003-11-21 | 2015-09-02 | UCB Biopharma SPRL | Method for the treatment of multiple sclerosis by inhibiting IL-17 activity |
US20060024268A1 (en) * | 2004-05-19 | 2006-02-02 | Wyeth | Modulation of immunoglobulin production and atopic disorders |
EP1773394A2 (en) * | 2004-08-05 | 2007-04-18 | Wyeth a Corporation of the State of Delaware | Antagonizing interleukin-21 receptor activity |
EP2322622A3 (en) * | 2005-03-25 | 2012-03-07 | National Research Council of Canada | Method for isolation of soluble polypeptides |
GT200600148A (es) | 2005-04-14 | 2006-11-22 | Metodos para el tratamiento y la prevencion de fibrosis | |
EP2567973B1 (en) | 2005-11-28 | 2014-05-14 | Zymogenetics, Inc. | IL-21 antagonists |
JP2009517406A (ja) * | 2005-11-28 | 2009-04-30 | ザイモジェネティクス, インコーポレイテッド | Il−21受容体アンタゴニスト |
PL2540820T3 (pl) | 2005-12-09 | 2018-05-30 | Academisch Medisch Centrum Bij De Universiteit Van Amsterdam | Środki i sposoby wpływania na stabilność komórek wytwarzających przeciwciała |
US9005974B2 (en) | 2005-12-09 | 2015-04-14 | Academish Medisch Centrum Bij De Universiteit Van Amsterdam | Means and methods for influencing the stability of cells |
US20070253950A1 (en) * | 2006-03-21 | 2007-11-01 | Wyeth | Methods for Preventing and Treating Amyloidogenic Diseases |
WO2008092084A2 (en) * | 2007-01-26 | 2008-07-31 | Centocor, Inc. | Injectable non-aqueous suspension with high concentration of therapeutic agent |
EP3351557A1 (en) | 2007-06-29 | 2018-07-25 | F. Hoffmann-La Roche AG | Heavy chain mutant leading to improved immunoglobulin production |
WO2009023267A2 (en) * | 2007-08-15 | 2009-02-19 | President And Fellows Of Harvard College | Methods for modulating development and expansion of il-17 expressing cells |
AU2008364115B2 (en) * | 2007-12-07 | 2013-11-21 | Zymogenetics, Inc. | Anti-human IL-21 monoclonal antibodies |
WO2009111889A1 (en) * | 2008-03-13 | 2009-09-17 | The Hospital For Sick Children | Lymphocyte control of obesity and insulin resistance |
CN102149403A (zh) * | 2008-05-23 | 2011-08-10 | 惠氏有限责任公司 | 利用白介素-21受体结合蛋白的治疗方法 |
PE20100141A1 (es) * | 2008-05-23 | 2010-02-22 | Wyeth Corp | Proteina de union al receptor de interleuquina 21 |
JP2012504939A (ja) | 2008-09-23 | 2012-03-01 | ワイス・エルエルシー | 架橋結合タンパク質による活性化シグナルの産生を予測するための方法 |
US8877199B2 (en) | 2009-05-15 | 2014-11-04 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | B cell surface reactive antibodies |
DK2454283T3 (en) | 2009-07-15 | 2018-05-07 | Aimm Therapeutics Bv | METHODS AND PROCEDURES FOR MANUFACTURING HIGH EFFICIENCY ANTIBODIES |
EP2596023A4 (en) * | 2010-07-20 | 2014-03-05 | Beth Israel Hospital | COMPOSITIONS AND METHODS COMPRISING ANTAGONISTS OF IL-6 AND IL-21 |
JP6013356B2 (ja) | 2010-12-02 | 2016-10-25 | アイム・セラピューティクス・べー・フェー | 高親和性抗体を製造するための手段および方法 |
EA027410B1 (ru) * | 2011-04-29 | 2017-07-31 | Селекта Байосайенсиз, Инк. | Наноносители, вызывающие иммунную толерантность, для снижения ответной реакции цитотоксических t-лимфоцитов |
US9309318B2 (en) | 2012-10-17 | 2016-04-12 | Amgen, Inc. | Compositions relating to anti-IL-21 receptor antibodies |
WO2014153195A1 (en) | 2013-03-14 | 2014-09-25 | Bayer Healthcare Llc | Monoclonal antibodies against antithrombin beta complexed with heparin |
WO2015115892A1 (en) | 2014-01-31 | 2015-08-06 | Aimm Therapeutics B.V. | Means and methods for producing stable antibodies |
AR099625A1 (es) * | 2014-03-21 | 2016-08-03 | Lilly Co Eli | Anticuerpos de il-21 |
RU2708336C2 (ru) | 2014-04-08 | 2019-12-05 | Бостон Фармасьютикалс Инк. | Связывающие молекулы, специфичные к ил-21, и области их применения |
EP3368656A4 (en) * | 2015-10-30 | 2019-07-17 | The United States of America, as represented by the secretary, Department of Health and Human Services | TARGETED CANCER THERAPY |
EP3436060A4 (en) * | 2016-03-31 | 2019-12-04 | Eli Lilly and Company | ANTIBODIES AGAINST IL-21 AND USES THEREOF |
ES2949342T3 (es) * | 2016-06-17 | 2023-09-27 | Medigene Immunotherapies Gmbh | Receptores de células T y usos de los mismos |
WO2018045273A2 (en) * | 2016-09-02 | 2018-03-08 | The Brigham And Women's Hospital, Inc. | Compositions and methods for treating neoplasias |
CN109503715B (zh) * | 2017-09-15 | 2023-12-15 | 科济生物医药(上海)有限公司 | Il-4r的融合蛋白及其应用 |
JP2022539351A (ja) * | 2019-06-26 | 2022-09-08 | ザ・ジョンズ・ホプキンス・ユニバーシティ | 制御性t細胞をターゲットとして増殖させるための方法及び材料 |
CN114901687A (zh) * | 2019-12-24 | 2022-08-12 | 迪哲(江苏)医药股份有限公司 | 新颖抗fgfr2b抗体 |
WO2023023150A2 (en) * | 2021-08-18 | 2023-02-23 | Hifibio (Hk) Limited | Methods and compositions related to neutralizing antibodies against human coronavirus |
WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
Family Cites Families (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
JPS5896026A (ja) | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
US4609546A (en) | 1982-06-24 | 1986-09-02 | Japan Chemical Research Co., Ltd. | Long-acting composition |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
EP0272253A4 (en) | 1986-03-07 | 1990-02-05 | Massachusetts Inst Technology | METHOD FOR IMPROVING GLYCOPROTE INSTABILITY. |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
US5011912A (en) | 1986-12-19 | 1991-04-30 | Immunex Corporation | Hybridoma and monoclonal antibody for use in an immunoaffinity purification system |
WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
GB8905669D0 (en) | 1989-03-13 | 1989-04-26 | Celltech Ltd | Modified antibodies |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
US5667988A (en) | 1992-01-27 | 1997-09-16 | The Scripps Research Institute | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
EP0714409A1 (en) | 1993-06-16 | 1996-06-05 | Celltech Therapeutics Limited | Antibodies |
CA2196200A1 (en) | 1994-07-29 | 1996-02-15 | Michael Joseph Browne | Novel compounds |
FR2724182B1 (fr) * | 1994-09-02 | 1996-12-13 | Pasteur Institut | Obtention d'un anticorps monoclonal recombinant a partir d'un anticorps monoclonal humain anti-rhesus d, sa production en cellules d'insecte, et ses utilisations |
SI9720020B (en) | 1996-02-09 | 2001-12-31 | Basf Ag | Human antibodies that bind human TNF alpha |
GB9610967D0 (en) | 1996-05-24 | 1996-07-31 | Cambridge Antibody Tech | Specific binding members,materials and methods |
EP0812913A3 (en) | 1996-06-12 | 1999-08-04 | Smithkline Beecham Corporation | HR-1 receptor, a receptor of the cytokine receptors family |
WO1997047741A1 (en) | 1996-06-12 | 1997-12-18 | Smithkline Beecham Corporation | Hr-1 receptor |
WO1997047742A1 (en) | 1996-06-12 | 1997-12-18 | Smithkline Beecham Corporation | Hr-1 receptor |
AUPO224696A0 (en) | 1996-09-11 | 1996-10-03 | Amrad Operations Pty. Limited | A novel haemopoietin receptor and genetic sequences encoding same |
JP2001508309A (ja) | 1997-01-16 | 2001-06-26 | ジェネティックス・インスチチュート・インコーポレーテッド | ヘマトポイエチン受容体スーパーファミリーのメンバー |
US6350892B1 (en) | 1997-09-23 | 2002-02-26 | Bristol-Myers Squibb Company | Trifluoromethyl ketone analogs as selective cPLA2 inhibitors |
US20010025022A1 (en) | 1997-11-26 | 2001-09-27 | Kikly Kristine Kay | Hnovilr |
US7189400B2 (en) | 1998-03-17 | 2007-03-13 | Genetics Institute, Llc | Methods of treatment with antagonists of MU-1 |
US6057128A (en) | 1998-03-17 | 2000-05-02 | Genetics Institute, Inc. | MU-1, member of the cytokine receptor family |
US7198789B2 (en) | 1998-03-17 | 2007-04-03 | Genetics Institute, Llc | Methods and compositions for modulating interleukin-21 receptor activity |
AU759689B2 (en) | 1998-06-24 | 2003-04-17 | Chugai Seiyaku Kabushiki Kaisha | Novel hemopoietin receptor proteins |
AU5104799A (en) | 1998-08-04 | 2000-02-28 | Regeneron Pharmaceuticals, Inc. | Novel orphan cytokine receptors |
US6576744B1 (en) | 1998-09-23 | 2003-06-10 | Zymogenetics, Inc. | Cytokine receptor zalpha11 |
US6803451B2 (en) | 1998-09-23 | 2004-10-12 | Zymogenetics, Inc. | Cytokine receptor zalpha11 polypeptides |
DK1115862T3 (da) | 1998-09-23 | 2009-11-16 | Zymogenetics Inc | Cytokinreceptor Zalpha11 |
US6355788B1 (en) * | 1998-10-15 | 2002-03-12 | Zymogenetics, Inc. | Follistatin-related protein zfsta2 |
EP1124851A1 (en) | 1998-11-06 | 2001-08-22 | Smithkline Beecham Corporation | Hnovilr |
ATE377076T1 (de) | 1999-03-09 | 2007-11-15 | Zymogenetics Inc | Humanes cytokin als ligand des zalpha rezeptors und dessen verwendungen |
US6307024B1 (en) | 1999-03-09 | 2001-10-23 | Zymogenetics, Inc. | Cytokine zalpha11 Ligand |
IL145134A0 (en) | 1999-03-25 | 2002-06-30 | Knoll Gmbh | Human antibodies that bind human il-12 and methods for producing |
WO2000069880A1 (en) | 1999-05-18 | 2000-11-23 | Millennium Pharmaceuticals, Inc. | Il-9/il-2 receptor-like molecules and uses thereof |
US20020090680A1 (en) | 1999-05-18 | 2002-07-11 | Millennium Pharmaceuticals, Inc. | Novel IL-9/IL-2 receptor-like molecules and uses thereof |
EP1212422B1 (en) | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
AU7676300A (en) | 1999-10-12 | 2001-04-23 | Cambridge Antibody Technology Limited | Human anti-adipocyte monoclonal antibodies and their use |
EP1230368A2 (en) | 1999-11-18 | 2002-08-14 | Schering Corporation | Mammalian receptor proteins; related reagents and methods |
BR0107862A (pt) | 2000-01-27 | 2002-11-05 | American Cyanamid Co | Método para a preparação de derivados do ácido alfa-sulfonil hidroxâmico |
DE60125543T2 (de) * | 2000-04-05 | 2007-10-04 | Zymogenetics, Inc., Seattle | Löslicher zytokinrezeptor zalpha11 |
AU6308801A (en) | 2000-05-11 | 2001-11-20 | Genetics Inst | Mu-1, member of the cytokine receptor family |
NZ522700A (en) * | 2000-06-16 | 2006-02-24 | Human Genome Sciences Inc | Antibodies that immunospecifically bind to blys |
EP1432431B1 (en) * | 2001-10-04 | 2017-05-10 | Genetics Institute LLC | Methods and compositions for modulating interleukin-21 activity |
AU2002336676A1 (en) | 2001-11-05 | 2003-05-19 | Zymogenetics, Inc | Il-21 antagonists |
US20040016010A1 (en) * | 2002-04-17 | 2004-01-22 | Marion Kasaian | IL-21 receptor knockout animal and methods of use thereof |
WO2004007682A2 (en) * | 2002-07-15 | 2004-01-22 | Wyeth | Methods and compositions for modulating t helper (th) cell development and function |
RU2005131852A (ru) | 2003-03-14 | 2006-04-20 | Уайт (Us) | Антитела против человеческого рецептора il-21 и их применение |
CN1849131A (zh) * | 2003-03-21 | 2006-10-18 | Wyeth公司 | 用白介素-21/白介素-21受体的激动剂治疗免疫性疾病 |
US20060024268A1 (en) * | 2004-05-19 | 2006-02-02 | Wyeth | Modulation of immunoglobulin production and atopic disorders |
EP1773394A2 (en) | 2004-08-05 | 2007-04-18 | Wyeth a Corporation of the State of Delaware | Antagonizing interleukin-21 receptor activity |
GT200600148A (es) * | 2005-04-14 | 2006-11-22 | Metodos para el tratamiento y la prevencion de fibrosis | |
WO2009100035A2 (en) | 2008-02-01 | 2009-08-13 | Wyeth | Interleukin-21 (il-21) and il-21 receptor (il-21r) modulation of regulatory t cells and forkhead box p3 (foxp3) |
-
2004
- 2004-03-12 RU RU2005131852/13A patent/RU2005131852A/ru not_active Application Discontinuation
- 2004-03-12 AU AU2004221876A patent/AU2004221876B2/en not_active Ceased
- 2004-03-12 EP EP04720349A patent/EP1603949B9/en not_active Revoked
- 2004-03-12 CN CNA2004800105188A patent/CN1777621A/zh active Pending
- 2004-03-12 WO PCT/US2004/007444 patent/WO2004083249A2/en active Application Filing
- 2004-03-12 MX MXPA05009556A patent/MXPA05009556A/es active IP Right Grant
- 2004-03-12 ES ES04720349T patent/ES2340280T3/es not_active Expired - Lifetime
- 2004-03-12 CN CN2010101657309A patent/CN102040662A/zh active Pending
- 2004-03-12 CA CA002518371A patent/CA2518371A1/en not_active Abandoned
- 2004-03-12 JP JP2006507081A patent/JP4914209B2/ja not_active Expired - Fee Related
- 2004-03-12 BR BRPI0408315-6A patent/BRPI0408315A/pt not_active IP Right Cessation
- 2004-03-12 NZ NZ542306A patent/NZ542306A/en unknown
- 2004-03-12 DE DE602004025332T patent/DE602004025332D1/de not_active Expired - Lifetime
- 2004-03-12 AT AT04720349T patent/ATE456581T1/de not_active IP Right Cessation
- 2004-03-12 EP EP09178337A patent/EP2184298A1/en not_active Withdrawn
- 2004-03-12 KR KR1020057017254A patent/KR20050119120A/ko not_active Application Discontinuation
- 2004-03-12 US US10/798,380 patent/US7495085B2/en not_active Expired - Fee Related
- 2004-03-15 CL CL200400534A patent/CL2004000534A1/es unknown
- 2004-03-15 AR ARP040100859A patent/AR043616A1/es unknown
-
2005
- 2005-09-02 ZA ZA200507067A patent/ZA200507067B/xx unknown
- 2005-09-07 NO NO20054170A patent/NO20054170L/no not_active Application Discontinuation
- 2005-09-14 CO CO05093185A patent/CO5660297A2/es not_active Application Discontinuation
-
2009
- 2009-01-14 US US12/353,812 patent/US8143385B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CL2004000534A1 (es) | 2005-03-04 |
ZA200507067B (en) | 2006-12-27 |
DE602004025332D1 (de) | 2010-03-18 |
US8143385B2 (en) | 2012-03-27 |
WO2004083249A2 (en) | 2004-09-30 |
WO2004083249A3 (en) | 2004-12-09 |
CN102040662A (zh) | 2011-05-04 |
CO5660297A2 (es) | 2006-07-31 |
MXPA05009556A (es) | 2005-11-16 |
KR20050119120A (ko) | 2005-12-20 |
US20100297151A1 (en) | 2010-11-25 |
EP2184298A1 (en) | 2010-05-12 |
US20040265960A1 (en) | 2004-12-30 |
NZ542306A (en) | 2008-04-30 |
US7495085B2 (en) | 2009-02-24 |
EP1603949B8 (en) | 2010-03-10 |
EP1603949B1 (en) | 2010-01-27 |
NO20054170D0 (no) | 2005-09-07 |
BRPI0408315A (pt) | 2006-03-07 |
JP2007525159A (ja) | 2007-09-06 |
AU2004221876A1 (en) | 2004-09-30 |
ATE456581T1 (de) | 2010-02-15 |
CA2518371A1 (en) | 2004-09-30 |
RU2005131852A (ru) | 2006-04-20 |
EP1603949B9 (en) | 2011-02-02 |
CN1777621A (zh) | 2006-05-24 |
ES2340280T3 (es) | 2010-06-01 |
EP1603949A2 (en) | 2005-12-14 |
AU2004221876B2 (en) | 2011-05-26 |
JP4914209B2 (ja) | 2012-04-11 |
AR043616A1 (es) | 2005-08-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20054170L (no) | Antistoff mot human IL-21 reseptor og anvendelser derav | |
NO20083715L (no) | Antistoffer mot human IL-22 og anvendelser derav | |
NO20083697L (no) | Fremgangsmater for anvendelse av antistoffer mot human IL-22 | |
NO20053389D0 (no) | Antistoffer mot PD-1 og deres anvendelser. | |
EA201000424A1 (ru) | Антитела к il-23 | |
MA35208B1 (fr) | Protéines de liaison à bcma (cd269/tnfrsf17) | |
EA201890145A1 (ru) | Антитела к фактору xi и способы их применения | |
TW200738748A (en) | Human monoclonal antibody human CD134 (OX40) and methods of making and using same | |
EA200800812A1 (ru) | Композиции антитела против cd3 | |
EA201100694A1 (ru) | Антитело к cd38 человека и его применение | |
EA201290589A1 (ru) | Cd127-связывающие белки | |
EA202192090A1 (ru) | Антигенсвязывающие белки против гамма-цепи рецептора il2 | |
EA200701092A1 (ru) | Антигенные эпитопы интерлейкина-21, связанные с ними антитела и их применение в медицине | |
WO2020136145A3 (en) | Leucocyte immunoglobulin-like receptor 2 neutralizing antibodies | |
EA202190138A1 (ru) | Анти-sirp-бета1 антитела и способы их использования | |
EA202092518A1 (ru) | Композиции и способы лечения рака | |
MX2021011715A (es) | Anticuerpos contra amiloide-? con piroglutamato y usos de estos campo de la invención. | |
MY149448A (en) | Interleukin-21 receptor binding proteins | |
WO2021263167A3 (en) | Il-10 muteins and fusion proteins thereof | |
EA202192488A1 (ru) | Антитела против tsg-6 и их применения | |
ECSP056015A (es) | Anticuerpos contra el receptor de il-21 humano y usos de los mismos | |
WO2024030956A3 (en) | Cd39-specific binding agents and methods of using the same | |
WO2023023489A3 (en) | Bispecific anti-flt3/cd3 antibodies and methods of use | |
MX2022008745A (es) | Anticuerpos anti-nkp30 y metodos de uso. | |
EA201992324A1 (ru) | Анти-trem2 антитела и способы их применения |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |